<\/p>\r\n\n
Goals<\/strong><\/td>| Long-term monitoring of safety and efficacy of therapy with biologics, biosimilars and JAK inhibitors in patients with rheumatoid arthritis (RA) compared to therapy with conventional, synthetic DMARDs<\/td>\n<\/tr>\n | Study design<\/strong><\/td> | Prospective observational study<\/td>\n<\/tr>\n | Participating physicians<\/strong><\/td> | Rheumatologists in practice or special outpatient departments throughout Germany. The participation of new facilities is possible at any time! Please register via the contact form<\/td>\n<\/tr>\n | Inclusion criteria<\/strong><\/td> | Patients with confirmed RA diagnosis by the rheumatologist stating the ACR criteria of 1987, | \ndisability age >=16 years, \ntherapy: \nstart of a new therapy with a biologic, biosimilar or JAK inhibitor or \nrestart of a therapy with a biologic, biosimilar or JAK inhibitor - without exception - after at least a three-month therapy break or \nstart of a therapy with a conventional DMARD after failure of at least a conventional DMARD therapy. \n \nHere <\/a>we provide a list of all currently approved therapies. \n \n(01\/2024)<\/td>\n<\/tr>\n Data collection<\/strong><\/td> | Questionnaires for physician and patient at the time of inclusion (at the beginning of the new therapy), after 3 and 6 months and at 6-month intervals thereafter<\/td>\n<\/tr>\n | Observation time<\/strong><\/td> | At least 5 years<\/td>\n<\/tr>\n | Time required for the physician<\/strong><\/td> | For the base bow approx. 15-30 minutes per patient, | \nfor a follow-up sheet about 10 to 15 minutes per patient<\/td>\n<\/tr>\n Study management<\/strong><\/td> | Pharmacoepidemiology working group of the German Rheumatism Research Center in Berlin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\r\n | <\/p>\r\n |